دورية أكاديمية
أعرض في EDS

Are In Vitro Human Blood-Brain-Tumor-Barriers Suitable Replacements for In Vivo Models of Brain Permeability for Novel Therapeutics?

التفاصيل البيبلوغرافية
العنوان: Are In Vitro Human Blood-Brain-Tumor-Barriers Suitable Replacements for In Vivo Models of Brain Permeability for Novel Therapeutics?
المؤلفون: Prashanth A; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia., Donaghy H; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia., Stoner SP; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia., Hudson AL; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia., Wheeler HR; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia.; Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia., Diakos CI; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia.; Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia., Howell VM; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia., Grau GE; Vascular Immunology, Department of Pathology, School of Pathology, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia., McKelvey KJ; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW 2065, Australia.
المصدر: Cancers [Cancers (Basel)] 2021 Feb 25; Vol. 13 (5). Date of Electronic Publication: 2021 Feb 25.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: High grade gliomas (HGG) are incapacitating and prematurely fatal diseases. To overcome the poor prognosis, novel therapies must overcome the selective and restricted permeability of the blood-brain barrier (BBB). This study critically evaluated whether in vitro human normal BBB and tumor BBB (BBTB) are suitable alternatives to "gold standard" in vivo models to determine brain permeability.
Methods: A systematic review utilizing the PRISMA guidelines used English and full-text articles from the past 5 years in the PubMed, Embase, Medline and Scopus databases. Experimental studies employing human cell lines were included.
Results: Of 1335 articles, the search identified 24 articles for evaluation after duplicates were removed. Eight in vitro and five in vivo models were identified with the advantages and disadvantages compared within and between models, and against patient clinical data where available. The greatest in vitro barrier integrity and stability, comparable to in vivo and clinical permeability data, were achieved in the presence of all cell types of the neurovascular unit: endothelial cells, astrocytes/glioma cells, pericytes and neurons.
Conclusions: In vitro co-culture BBB models utilizing stem cell-derived or primary cells are a suitable proxy for brain permeability studies in order to reduce animal use in medical research.
References: Front Cell Neurosci. 2019 Jun 06;13:230. (PMID: 31244605)
FASEB J. 2005 Nov;19(13):1872-4. (PMID: 16141364)
Theranostics. 2020 May 15;10(14):6361-6371. (PMID: 32483457)
Bioeng Transl Med. 2019 Jan 13;4(2):e10126. (PMID: 31249876)
Mol Pharm. 2019 Nov 4;16(11):4461-4471. (PMID: 31573814)
Biomed Res Int. 2015;2015:320941. (PMID: 25866775)
Ann Biomed Eng. 2020 Feb;48(2):780-793. (PMID: 31741228)
Nat Rev Cancer. 2020 Jan;20(1):26-41. (PMID: 31601988)
Drug Resist Updat. 2015 Mar;19:1-12. (PMID: 25791797)
NPJ Vaccines. 2020 Jan 16;5(1):5. (PMID: 31969991)
Circ Res. 2017 Jan 6;120(1):179-206. (PMID: 28057793)
Sci Rep. 2019 Nov 5;9(1):16310. (PMID: 31690750)
Front Neuroeng. 2013 Aug 30;6:7. (PMID: 24009582)
Stem Cells. 2018 Dec;36(12):1816-1827. (PMID: 30171748)
J Control Release. 2018 Nov 10;289:14-22. (PMID: 30243824)
Sci Rep. 2020 Jul 23;10(1):12358. (PMID: 32704093)
Pharmacol Rev. 2005 Jun;57(2):173-85. (PMID: 15914466)
Nat Commun. 2020 Jan 10;11(1):175. (PMID: 31924752)
Pharm Res. 2013 Nov;30(11):2729-56. (PMID: 23801086)
J Biomech Eng. 2014 Mar;136(3):031005. (PMID: 24193698)
Front Psychiatry. 2012 May 11;3:47. (PMID: 22593745)
PLoS One. 2017 Oct 23;12(10):e0187017. (PMID: 29059256)
Int J Pharm. 2015 Jul 25;490(1-2):94-101. (PMID: 25981617)
RSC Adv. 2017;7(68):42811-42818. (PMID: 29308191)
Eur J Neurosci. 2018 Jun;47(12):1444-1456. (PMID: 29738614)
Open Med. 2009;3(3):e123-30. (PMID: 21603045)
Micromachines (Basel). 2019 Jun 05;10(6):. (PMID: 31195652)
Microvasc Res. 2009 Mar;77(2):166-73. (PMID: 18838082)
Brain Res. 2009 Nov 17;1298:13-23. (PMID: 19728990)
Mol Pharm. 2016 Dec 5;13(12):4191-4198. (PMID: 27934481)
Fluids Barriers CNS. 2020 Jun 2;17(1):37. (PMID: 32487241)
Front Neurosci. 2017 Apr 21;11:224. (PMID: 28484368)
J Neurooncol. 2017 Jan;131(1):1-9. (PMID: 27743144)
Sci Rep. 2019 Mar 7;9(1):3826. (PMID: 30846769)
Nat Rev Neurosci. 2006 Jan;7(1):41-53. (PMID: 16371949)
Nat Commun. 2017 Jun 06;8:15623. (PMID: 28585535)
Biores Open Access. 2019 Nov 14;8(1):200-209. (PMID: 31737437)
PLoS One. 2013;8(1):e55166. (PMID: 23383092)
Biomaterials. 2018 Oct;180:117-129. (PMID: 30032046)
Stem Cell Reports. 2019 Mar 5;12(3):474-487. (PMID: 30773484)
Acta Physiol (Oxf). 2014 Apr;210(4):790-8. (PMID: 24629161)
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):. (PMID: 33542154)
Biotechnol Bioeng. 2017 Jan;114(1):184-194. (PMID: 27399645)
Neurol Res. 2018 Feb;40(2):117-121. (PMID: 29100486)
Sci Rep. 2020 Mar 2;10(1):3788. (PMID: 32123236)
J Pharm Pharmacol. 2017 Dec;69(12):1684-1696. (PMID: 28872681)
Int J Pharm. 2018 Nov 15;551(1-2):281-289. (PMID: 30240829)
Fluids Barriers CNS. 2018 Aug 31;15(1):23. (PMID: 30165870)
معلومات مُعتمدة: 1357 Hunter Medical Research Institute; 780 Hunter Medical Research Institute; 1096 Hunter Medical Research Institute
فهرسة مساهمة: Keywords: blood brain barrier; brain cancer; brain microvascular endothelial cells; diffuse intrinsic pontine glioma; glioblastoma; induced pluripotent stem cells; neurovascular unit; permeability; tight junctions; transendothelial electrical resistance
تواريخ الأحداث: Date Created: 20210306 Latest Revision: 20240818
رمز التحديث: 20240818
مُعرف محوري في PubMed: PMC7956470
DOI: 10.3390/cancers13050955
PMID: 33668807
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13050955